Cyclin-dependent kinase 9 inhibitors in solid form and their uses
By providing solid crystalline form and specific crystal form of CDK9 inhibitor, combined with pharmaceutical carriers, the problem of insufficient efficacy and safety of existing CDK9 inhibitors is solved, and effective inhibition of CDK9 and inhibition of multiple tumor cells is achieved. Reduces the risk of cardiotoxicity and improves the potential of patent medicines.
Patent Information
- Application Number
- CN202210647694.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-06-09
- Filing Date
- 2022-06-08
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2042-06-08
AI Technical Summary
The existing CDK9 inhibitors do not yet have good efficacy, good safety and good drug potential, and are difficult to widely use in clinical practice, and are insufficiently selective to other CDK subtypes, affecting their anti-tumor effects.
Provide a solid form of CDK9 inhibitor compound, specifically its crystalline form and crystal form I, crystal form V, and crystal form XIII. It ensures its high crystallinity and stability through X-ray powder diffraction pattern, DSC and TGA analysis. and selectively prepared into pharmaceutical compositions in combination with pharmaceutical carriers for the treatment of CDK9-mediated diseases.
The compounds have good in vitro kinase inhibitory activity and selectivity on CDK9, and show strong inhibitory effects on a variety of tumor cells. The results of in vivo anti-tumor tests show better safety and effects, reducing the risk of cardiotoxicity, and having higher drug use possibility.
Smart Images

Figure CN115448874B_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims priority to Chinese Patent Application No. 202110644313.0 filed on June 9, 2021, and the entire contents of that application are incorporated herein by reference in their entirety for all purposes. Technical Field
[0003] The present application relates to a solid compound as a cyclin-dependent kinase 9 (CDK9) inhibitor, and its use in preparing a drug for treating CDK9-related diseases. Background Art
[0004] Cyclin-dependent kinases (CDKs) are a class of serine / threonine protein kinases that play a key role in regulating the cell cycle and transcription. To date, there are about 20 human CDK subtypes and about 30 cell cycle chaperone proteins. These CDKs can be activated by cell cycle proteins and play different biological functions. CDKs can be divided into two types according to their functions, one controls the cell cycle and the other regulates cell transcription. For example, CDK1, 2, 3, 4, and 6 directly intervene in the cell cycle; CDK5 does not regulate the cell cycle, but plays a key role in the complex migration of post-mitotic neurons; CDK7 indirectly acts as an activator of these CDKs; CDK9 only plays a role in cell transcription and does not participate in the regulation of the cell cycle.
[0005] CDK9 is an important member of the transcriptional CDKs subfamily, which is a group of kinases that function to control the main steps of eukaryotic RNA polymerase II (Pol II) synthesis and processing of mRNA. CDK9 is present in all mammalian cells. The activation of CDK9 in vivo depends on its binding to the corresponding cyclin (Cyclin T / K) to form a heterodimer, namely positive transcription elongation factor b (P-TEFb). When negative transcription elongation factors (NELFs) participate in the negative regulation of cell transcription, transcription is inhibited, and P-TEFb is recruited to the system where negative transcription elongation factors inhibit transcription elongation, catalyzing the phosphorylation of the carbon terminal domain (CTD) of RNA polymerase II, and at the same time catalyzing the phosphorylation of the SPT5 subunit of NELFs and the RD subunit of NELF, causing the negative transcription elongation factor to detach from the transcription complex, thereby allowing transcription to continue.
[0006] Tumors are usually caused by the loss of cyclin-dependent kinase inhibitor (CDKI) expression or the overexpression of cyclins, which leads to unregulated cell proliferation. In view of the above regulatory mechanism, the use of CDK9 inhibitors will be able to prevent P-TEFb from phosphorylating the carbon-terminal domain of RNA polymerase II, further hindering the departure of NEFL, strengthening the negative inhibitory effect, causing transcription to stop, and causing the levels of intracellular mRNA and short-lived proteins to drop rapidly, thereby causing apoptosis of tumor cells. CDK9 has become a potential protein target for the development of effective cancer treatments. Recently, pharmaceutical companies have conducted research on the use of CDK9 inhibitors for cancer treatment. For example, AstraZeneca's AZD4573 and Bayer's BAY-1251152 are both in Phase I clinical trials.
[0007] Although some CDK9 inhibitor small molecules have been disclosed (for example, WO2009047359, WO2014076091, etc.), no drug has been approved for marketing yet. It is still necessary to develop new compounds with good efficacy, good safety, and good drug potential so that more patients can benefit clinically. Summary of the invention
[0008] In one aspect, the present application provides a compound of formula (A) in solid form,
[0009]
[0010] In another aspect, the present application provides a crystalline compound of formula (A).
[0011] In some embodiments of the present application, the above-mentioned crystalline form is characterized in that the crystalline form is a solvent-free and anhydrous crystalline form or a hydrate crystalline form, preferably a solvent-free and anhydrous crystalline form.
[0012] On the other hand, the present application provides a crystalline form I of the compound represented by formula (A), which has an X-ray powder diffraction pattern using Cu-Kα radiation and has characteristic diffraction peaks at the following 2θ angles: 13.3±0.2°, 19.4±0.2°, 20.1±0.2°.
[0013] In some schemes of the present application, the above-mentioned Form I, using Cu-Kα radiation, has an X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2θ angles: 13.3±0.2°, 19.4±0.2°, 20.1±0.2°, and 23.0±0.2°.
[0014] In some schemes of the present application, the above-mentioned Form I, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 13.3±0.2°, 19.4±0.2°, 20.1±0.2°, 21.5±0.2°, 23.0±0.2°.
[0015] In some schemes of the present application, the above-mentioned Form I, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 13.3±0.2°, 19.4±0.2°, 20.1±0.2°, 23.0±0.2°, 26.1±0.2°.
[0016] In some schemes of the present application, the above-mentioned Form I, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 13.3±0.2°, 19.4±0.2°, 20.1±0.2°, 20.7±0.2°, 21.5±0.2°, 23.0±0.2°, 26.1±0.2°.
[0017] In some schemes of the present application, the above-mentioned Form I, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 13.3±0.2°, 19.4±0.2°, 20.1±0.2°, 20.7±0.2°, 21.5±0.2°, 23.0±0.2°, 26.1±0.2°, 26.6±0.2°.
[0018] In some schemes of the present application, the above-mentioned Form I, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 9.3±0.2°, 13.3±0.2°, 19.4±0.2°, 20.1±0.2°, 20.7±0.2°, 21.5±0.2°, 23.0±0.2°, 26.1±0.2°, 26.6±0.2°.
[0019] In some schemes of the present application, the above-mentioned Form I, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 9.3±0.2°, 12.4±0.2°, 13.3±0.2°, 18.6±0.2°, 19.4±0.2°, 20.1±0.2°, 20.7±0.2°, 21.5±0.2°, 23.0±0.2°, 26.1±0.2°, 26.6±0.2°.
[0020] In some schemes of the present application, the above-mentioned Form I, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 9.3±0.2°, 12.4±0.2°, 13.3±0.2°, 18.6±0.2°, 19.4±0.2°, 20.1±0.2°, 20.4±0.2°, 20.7±0.2°, 21.5±0.2°, 22.0±0.2°, 23.0±0.2°, 26.1±0.2°, 26.6±0.2°.
[0021] In some schemes of the present application, the above-mentioned Form I, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 9.3±0.2°, 12.4±0.2°, 13.1±0.2°, 13.3±0.2°, 15.4±0.2°, 18.6±0.2°, 19.4±0.2°, 19.5±0.2°, 20.1±0.2°, 20.4±0.2°, 20.7±0.2°, 21.5±0.2°, 22.0±0.2°, 23.0±0.2°, 26.1±0.2°, 26.6±0.2°.
[0022] In some embodiments of the present application, the above-mentioned Form I, using Cu-Kα radiation, has an X-ray powder diffraction pattern having a characteristic diffraction peak (±0.2°) at the following 2θ angles:
[0023] Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % 9.3 16.2 19.4 100 22.0 27.6 12.4 14.5 19.5 69.7 23.0 61.0 13.1 39.7 20.1 71.3 26.1 61.2 13.3 67.3 20.4 48.1 26.6 39.7 15.4 16.8 20.7 46.2 18.6 25.6 21.5 43.2
[0024] In some embodiments of the present application, the above-mentioned Form I, using Cu-Kα radiation, has substantially the following Figure 1 The X-ray powder diffraction pattern is shown.
[0025] In some embodiments of the present application, the above-mentioned Form I has an endothermic peak at 204.33±5°C in its differential scanning calorimetry curve.
[0026] In some embodiments of the present application, the above-mentioned crystal form I has substantially the following Figure 2 DSC spectrum shown.
[0027] In some embodiments of the present application, the thermogravimetric analysis curve of the above-mentioned Form I shows a weight loss of 0.565%±0.2% between room temperature and 180°C±5°C.
[0028] In some embodiments of the present application, the above-mentioned crystal form I has substantially the following Figure 2 TGA spectrum shown.
[0029] On the other hand, the present application provides a crystalline form V of the compound represented by formula (A), which has an X-ray powder diffraction pattern using Cu-Kα radiation and has characteristic diffraction peaks at the following 2θ angles: 11.3±0.2°, 18.3±0.2°, 22.8±0.2°.
[0030] In some schemes of the present application, the above-mentioned form V, using Cu-Kα radiation, has an X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2θ angles: 11.3±0.2°, 16.2±0.2°, 18.3±0.2°, 21.0±0.2°, 22.8±0.2°.
[0031] In some schemes of the present application, the above-mentioned form V, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 11.3±0.2°, 16.2±0.2°, 18.3±0.2°, 21.0±0.2°, 22.8±0.2°, 23.5±0.2°.
[0032] In some schemes of the present application, the above-mentioned form V, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 9.4±0.2°, 11.3±0.2°, 16.2±0.2°, 18.3±0.2°, 19.7±0.2°, 21.0±0.2°, 22.8±0.2°, 23.5±0.2°.
[0033] In some schemes of the present application, the above-mentioned form V, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 6.5±0.2°, 9.4±0.2°, 11.3±0.2°, 16.2±0.2°, 16.7±0.2°, 18.3±0.2°, 19.7±0.2°, 21.0±0.2°, 22.8±0.2°, 23.5±0.2°.
[0034] In some schemes of the present application, the above-mentioned form V, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 6.5±0.2°, 9.4±0.2°, 11.3±0.2°, 16.2±0.2°, 16.7±0.2°, 17.0±0.2°, 18.3±0.2°, 19.7±0.2°, 20.7±0.2°, 21.0±0.2°, 22.8±0.2°, 23.5±0.2°.
[0035] In some schemes of the present application, the above-mentioned form V, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 6.5±0.2°, 9.4±0.2°, 11.3±0.2°, 13.1±0.2°, 16.2±0.2°, 16.7±0.2°, 17.0±0.2°, 18.3±0.2°, 19.7±0.2°, 20.7±0.2°, 21.0±0.2°, 22.8±0.2°, 23.5±0.2°, 24.4±0.2°.
[0036] In some embodiments of the present application, the above-mentioned crystal form V, using Cu-Kα radiation, has an X-ray powder diffraction pattern having a characteristic diffraction peak (±0.2°) at the following 2θ angles:
[0037] Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % 6.5 7.9 16.7 17.8 21.0 34.3 9.4 14.6 17.0 11.3 22.8 100.0 11.3 83.5 18.3 30.3 23.5 44.1 13.1 5.2 19.7 9.4 24.4 5.6 16.2 32.2 20.7 8.0
[0038] In some embodiments of the present application, the above-mentioned Form V, using Cu-Kα radiation, has substantially the following Figure 3 The X-ray powder diffraction pattern is shown.
[0039] In some embodiments of the present application, the above-mentioned crystal form V has an endothermic peak at 185.87±5°C in its differential scanning calorimetry curve.
[0040] In some embodiments of the present application, the above-mentioned crystal form V has substantially the following Figure 4 DSC spectrum shown.
[0041] In some embodiments of the present application, the thermogravimetric analysis curve of the above-mentioned Form V shows a weight loss of 0.926%±0.2% between room temperature and 170±5°C.
[0042] In some embodiments of the present application, the above-mentioned crystal form V has substantially the following Figure 4 TGA spectrum shown.
[0043] On the other hand, the present application provides a crystalline form XIII of the compound represented by formula (A), which has an X-ray powder diffraction pattern using Cu-Kα radiation and has characteristic diffraction peaks at the following 2θ angles: 15.8±0.2°, 19.1±0.2°, 20.8±0.2°.
[0044] In some schemes of the present application, the above-mentioned form XIII, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 14.3±0.2°, 15.8±0.2°, 17.8±0.2°, 19.1±0.2°, 20.8±0.2°.
[0045] In some schemes of the present application, the above-mentioned form XIII, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 9.5±0.2°, 14.3±0.2°, 15.8±0.2°, 17.8±0.2°, 19.1±0.2°, 20.8±0.2°, 24.4±0.2°.
[0046] In some schemes of the present application, the above-mentioned form XIII, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 9.5±0.2°, 14.3±0.2°, 15.8±0.2°, 17.8±0.2°, 18.2±0.2°, 19.1±0.2°, 20.8±0.2°, 24.4±0.2°, 26.3±0.2°.
[0047] In some schemes of the present application, the above-mentioned form XIII, using Cu-Kα radiation, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 9.5±0.2°, 14.3±0.2°, 15.8±0.2°, 16.6±0.2°, 17.8±0.2°, 18.2±0.2°, 19.1±0.2°, 20.8±0.2°, 24.4±0.2°, 26.3±0.2°, 26.9±0.2°.
[0048] In some embodiments of the present application, the above-mentioned Form XIII, using Cu-Kα radiation, has an X-ray powder diffraction pattern having a characteristic diffraction peak (±0.2°) at the following 2θ angles:
[0049]
[0050]
[0051] In some embodiments of the present application, the above-mentioned Form XIII, using Cu-Kα radiation, has substantially the following Figure 5 The X-ray powder diffraction pattern is shown.
[0052] In some schemes of the present application, the differential scanning calorimetry curve of the above-mentioned Form XIII has two endothermic peaks at 194.07±5°C and 200.51±5°C, respectively.
[0053] In some embodiments of the present application, the above-mentioned Form XIII has substantially the following Figure 6 DSC spectrum shown.
[0054] In some embodiments of the present application, the thermogravimetric analysis curve of the above-mentioned Form XIII shows a weight loss of 0.216%±0.2% between room temperature and 180±5°C.
[0055] In some embodiments of the present application, the above-mentioned Form XIII has substantially the following Figure 6 TGA spectrum shown.
[0056] Another object of the present application is to provide a crystalline composition comprising Form I, Form V, Form XIII or two or more thereof of the compound of formula (A).
[0057] In some embodiments of the present application, the crystalline form I accounts for more than 50%, more than 60%, more than 70%, more than 80%, more than 90% or more than 95% of the weight of the crystalline composition.
[0058] In some embodiments of the present application, the crystalline form V accounts for more than 50%, more than 60%, more than 70%, more than 80%, more than 90% or more than 95% of the weight of the crystalline composition.
[0059] In some embodiments of the present application, the Form XIII accounts for more than 50%, more than 60%, more than 70%, more than 80%, more than 90% or more than 95% of the weight of the crystalline composition.
[0060] Another object of the present application is to provide a pharmaceutical composition comprising a compound of formula (A) in solid form, a compound of formula (A) in crystalline form, or a crystalline combination thereof.
[0061] In some embodiments of the present application, the above-mentioned pharmaceutical composition comprises the crystalline form I, crystalline form V, or crystalline form XIII of the compound represented by formula (A).
[0062] Another object of the present application is to provide a pharmaceutical composition, which comprises a compound of formula (A) in solid form, a compound of formula (A) in crystalline form or a crystalline composition thereof, and a pharmaceutically acceptable carrier.
[0063] In some embodiments of the present application, the above-mentioned pharmaceutical composition comprises the crystalline form I, crystalline form V, or crystalline form XIII of the compound of formula (A), and a pharmaceutically acceptable carrier.
[0064] On the other hand, the present application also provides the use of the above-mentioned solid form of the compound of formula (A), the crystalline form of the compound of formula (A), the crystalline form I, the crystalline form V, the crystalline form XIII of the compound of formula (A), the above-mentioned crystalline composition or the above-mentioned pharmaceutical composition in the preparation of drugs for preventing and / or treating CDK9-mediated diseases.
[0065] In some embodiments of the present application, the above-mentioned use, wherein the CDK9-mediated disease includes a cell proliferative disease or an inflammatory disease.
[0066] On the other hand, the present application also provides the use of the compound of formula (A) in solid form, the compound of formula (A) in crystalline form, crystal form I, crystal form V, crystal form XIII of the compound of formula (A), the above-mentioned crystalline composition or the above-mentioned pharmaceutical composition in the preparation of a drug as a CDK9 inhibitor.
[0067] In some embodiments of the present application, the drug is used to treat CDK9-mediated diseases.
[0068] In some embodiments of the present application, the CDK9-mediated disease includes a cell proliferative disease or an inflammatory disease.
[0069] In some embodiments of the present application, the aforementioned CDK9-mediated disease refers to a disease involving changes in the CDK9 gene, protein, activity or expression thereof.
[0070] In some embodiments of the present application, the aforementioned cell proliferative disease or inflammatory disease involves changes in the CDK9 gene, protein, activity or expression thereof.
[0071] In some schemes of the present application, the aforementioned cell proliferative disease is a tumor; preferably, the tumor is a blood tumor or a solid tumor; preferably, a relapsed or refractory blood tumor or solid tumor; preferably, a malignant blood tumor or an advanced solid tumor; further preferably, an advanced malignant blood tumor or an advanced malignant solid tumor; further preferably, a relapsed or refractory advanced malignant blood tumor or an advanced malignant solid tumor.
[0072] In some embodiments of the present application, the blood tumor is leukemia, lymphoma or myeloma; preferably, the leukemia is acute myeloid leukemia; preferably, the lymphoma is non-Hodgkin's lymphoma; preferably, it is mantle cell lymphoma or diffuse large B-cell lymphoma; preferably, the myeloma is multiple myeloma.
[0073] In some embodiments of the present application, the solid tumor is selected from liver cancer, breast cancer and prostate cancer; preferably, the breast cancer is triple-negative breast cancer.
[0074] On the other hand, the present application also provides the use of the compound represented by formula (A) in solid form or the compound represented by formula (A) in crystalline form in the preparation of Form I, Form V, or Form XIII.
[0075] Definition and Description
[0076] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular phrase or term should not be considered ambiguous or unclear without special definition, but should be understood according to the ordinary meaning.
[0077] The "solid form of the compound represented by formula (A)" mentioned in the present application refers to the compound represented by formula (A) in solid form, including its crystalline form and amorphous form.
[0078] The "crystalline form of the compound represented by formula (A)" mentioned in the present application refers to the compound represented by formula (A) in crystalline form, including the anhydrous and solvent-free form, hydrate form, solvate form and co-crystal form of the compound represented by formula (A); preferably including the anhydrous and solvent-free form, hydrate form and solvate form of the compound represented by formula (A); preferably including the anhydrous and solvent-free form and hydrate form of the compound represented by formula (A).
[0079] The term "solvate" or "solvate" refers to a complex with variable stoichiometry formed by a solute (in the present application, a compound shown in formula (A)) and a solvent. Such solvents for the purposes of the present application must not interfere with the biological activity of the solute. Suitable solvates include pharmaceutically acceptable solvates, and also include both stoichiometric solvates and non-stoichiometric solvates. However, solvates with non-pharmaceutically acceptable solvents are within the scope of the present application, for example, they can be used as intermediates for the preparation of compounds shown in formula (A) or other crystalline forms. Preferably, the solvent used is water, in which case the resulting solvate may also be referred to as a hydrate. As used herein and unless otherwise indicated, the term "hydrate" refers to a compound provided herein that further includes stoichiometric or non-stoichiometric amounts of water bound by non-covalent intermolecular forces.
[0080] The "solvent-free and anhydrous crystalline form" means that the sample does not contain solvent molecules or water molecules that are bound to the compound represented by formula (A) by intermolecular forces. For example, when the sample is measured by thermogravimetric analysis (TGA), it contains no more than 3.0%, such as no more than 1.5%, such as no more than 1% water or solvent by weight.
[0081] The term "crystalline composition" refers to a solid form, which comprises the crystal form I, crystal form V, crystal form XIII or two or more thereof mentioned in the present application. Moreover, in addition to the crystal forms mentioned in the present application, the crystalline composition may optionally contain other crystal forms or other amorphous forms of the compound shown in formula (A) or its salt, or impurities other than these substances. It should be understood by those skilled in the art that the sum of the contents of each component in the crystalline composition should be 100%.
[0082] The term "optional" or "optionally" means that the event or situation described subsequently may or may not occur, and the description includes the occurrence of the event or situation and the non-occurrence of the event or situation. The "room temperature" is the room temperature in the conventional sense of the art, generally 10 to 30°C, preferably 25°C ± 5°C.
[0083] In the X-ray powder diffraction pattern, the term "substantially" or "substantially as shown in the figure..." refers to a substantially pure crystalline form, in which at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% of the peaks in the powder X-ray diffraction pattern appear in the given pattern. Further, when the content of a certain crystalline form in the product gradually decreases, some of the diffraction peaks attributable to the crystalline form in its X-ray powder diffraction pattern may become less due to the detection sensitivity of the instrument. In addition, for any given crystalline form, there may be slight errors in the position of the peak, which is also well known in the field of crystallography. For example, due to changes in temperature, sample movement or instrument calibration during sample analysis, the position of the peak can move, and the measurement error of the 2θ value is sometimes about ±0.2°. Therefore, this error should be taken into account when determining each crystalline structure, and the term "substantially" or "substantially as shown in the figure..." is also intended to cover such differences in the diffraction peak positions.
[0084] In a DSC spectrum or a TGA spectrum, the term "substantially" or "substantially as shown in the figure..." means that for the same crystal form of the same compound, in consecutive analyses, the error of the thermal transition onset temperature, the peak temperature of the endothermic peak, the peak temperature of the exothermic peak, the melting point, the starting temperature of weight loss or the end temperature of weight loss is typically within about 5°C, usually within about 3°C. When describing a compound as having a given thermal transition onset temperature, peak temperature of the endothermic peak, peak temperature of the exothermic peak, the melting point, the starting temperature of weight loss or the end temperature of weight loss, it refers to the temperature ±5°C.
[0085] As used herein, the term "cell proliferative disorder" refers to a condition in which a population of cells grows at a rate that is slower or faster than expected under given physiological conditions and circumstances.
[0086] The term "tumor" includes benign tumors, malignant tumors and borderline tumors, among which malignant tumors are collectively referred to as cancer.
[0087] As used herein, the term "prevent" or "preventing" means that when used for a disease or condition (e.g., cancer), the compound or drug (e.g., the combination product claimed herein) can reduce the frequency of symptoms of the medical condition in a subject or delay its onset compared to a subject to which the compound or drug (e.g., the combination product claimed herein) is not administered.
[0088] As used herein, the term "treat," "treat," "treat," "treat," or "treat" refers to alleviating, relieving, or ameliorating symptoms of a disease or condition, ameliorating underlying metabolically caused symptoms, inhibiting a disease or symptom, such as arresting the development of a disease or condition, alleviating a disease or condition, causing regression of a disease or condition, alleviating a condition caused by a disease or condition, or arresting symptoms of a disease or condition.
[0089] The pharmaceutical composition of the present application can be prepared by conventional methods in the art.
[0090] In the context of the present application, the term "pharmaceutically acceptable carrier" or "excipient" or "pharmaceutically acceptable excipient" or "pharmaceutically acceptable excipient" refers to those excipients that have no obvious irritation to the organism and do not damage the biological activity and performance of the active compound. The term "pharmaceutically acceptable excipient" includes: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, antioxidants, chelating agents, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids, release retardants, etc. Those skilled in the art can select specific pharmaceutically acceptable excipients according to actual needs. The knowledge about excipients is well known to those skilled in the art, for example, reference may be made to "Pharmaceutics" (edited by Cui Fude, 5th edition, People's Medical Publishing House, 2003).
[0091] The word "comprise" or "comprises" and its English variations such as comprises or comprising should be construed in an open and non-exclusive sense, ie, "including but not limited to".
[0092] In the scope of this application, various options of any feature can be combined with various options of other features to form many different embodiments. This application is intended to include all possible embodiments composed of various options of all technical features, as long as such new technical solutions are technically feasible.
[0093] Technical Effects
[0094] The solid form of the compound represented by formula (A), the crystalline form of the compound represented by formula (A) and the specific crystal form provided in the present application have one or more of the following beneficial effects:
[0095] The crystalline form and specific crystal form of the compound represented by formula (A) mentioned in the present application have good crystallinity and are easy to purify, filter and separate;
[0096] Easy to formulate into medicines, with good stability (e.g., solid stability, solution stability), especially Form I, Form V, and Form XIII;
[0097] It has no obvious hygroscopicity and has good medicinal prospects;
[0098] The results of in vitro kinase activity tests and cell tests showed that the compound (A) of the present application had good in vitro kinase inhibitory activity against CDK9, good selectivity against other CDK subtypes, and strong inhibitory effects against a variety of tumor cells;
[0099] In vitro hERG inhibitory activity tests show that the compound represented by formula (A) has a lower risk of cardiac toxicity;
[0100] The results of in vivo anti-tumor tests and safety tests showed that compared with the control compound, the compound represented by formula (A) has better in vivo anti-tumor effect, less toxicity, and higher drugability, providing a better choice for drugs that inhibit CDK9 targets. BRIEF DESCRIPTION OF THE DRAWINGS
[0101] Figure 1 : X-ray powder diffraction pattern of Form I of Example 1.
[0102] Figure 2 : DSC-TGA spectrum of Form I of Example 1.
[0103] Figure 3 : X-ray powder diffraction pattern of Form V of Example 2.
[0104] Figure 4 : DSC-TGA spectrum of Form V of Example 2.
[0105] Figure 5 : X-ray powder diffraction pattern of Form XIII of Example 3.
[0106] Figure 6 : DSC-TGA spectrum of Form XIII of Example 3. DETAILED DESCRIPTION
[0107] 1. X-ray powder diffractometer (XRPD)
[0108] Instrument model: Bruker D8 Advance X-ray powder diffractometer (Bruker, GER)
[0109] Test method: About 2 to 10 mg of sample is used for XRPD detection
[0110] The detailed XRPD parameters are as follows:
[0111] X-ray generator: Cu-Kα
[0112] Light tube voltage: 40kV, light tube current: 40mA
[0113] Scanning range: 3°-45°(2θ)
[0114] Scanning step: 0.02°
[0115] Exposure time: 0.12 seconds
[0116] Sample plate: Zero background sample plate
[0117] Acquisition software: DIFFRAC.Measurement Center (Bruker, GER)
[0118] Analysis software: DIFFRAC.EVA (Bruker, GER).
[0119] 2. Differential Scanning Calorimeter (DSC)
[0120] Instrument model: TA Discovery 2500 differential scanning calorimeter (TA, US)
[0121] Test method: Place the sample in a DSC sample pan, cover the sample pan and pierce it. After equilibration at 25°C, heat the sample to the final temperature at a heating rate of 10°C / min.
[0122] Sample amount: 1-2 mg
[0123] Air flow type: Nitrogen
[0124] Flow rate: 50mL / min
[0125] Heating start temperature: 25°C
[0126] Termination temperature: 250℃.
[0127] 3. Thermogravimetric analysis (TGA)
[0128] Instrument model: TA Discovery 55 Thermogravimetric Analyzer (TA, US)
[0129] Test method: Place the sample in a balanced open aluminum sample pan. After the sample mass is automatically weighed in the TGA heating furnace, heat the sample to the final temperature at a rate of 10°C / min.
[0130] Sample size: 2-5 mg
[0131] Air flow type: Nitrogen
[0132] Flow rate: 60mL / min
[0133] Heating starting temperature: room temperature
[0134] Termination temperature: 300℃.
[0135] 4. Dynamic moisture adsorption and desorption analysis (DVS)
[0136] Instrument model: DVS Intrinsic dynamic water vapor adsorption instrument (SMS, UK)
[0137] Test method: Add enough sample (15mg) to the instrument to simulate dynamic water vapor adsorption, and record the weight change at 25℃, in different humidity ranges from 0% to 90% (humidity change of each gradient is 10%, humidity change: 50%-95%-0%-50%). The gradient endpoint is judged by dm / dt method, and the gradient endpoint is determined when dm / dt is less than 0.002% and maintained for 10 minutes.
[0138] Classify the sample's hygroscopicity:
[0139] (1) Deliquescence: Absorbs enough water to form a liquid
[0140] (2) Highly hygroscopic: weight gain due to moisture absorption is not less than 15%
[0141] (3) Hygroscopic: The weight gain due to moisture absorption is less than 15% but not less than 2%
[0142] (4) Slightly hygroscopic: the weight gain due to moisture absorption is less than 2% but not less than 0.2%
[0143] (5) Non-hygroscopic: Moisture absorption weight gain is less than 0.2%.
[0144] 5. High Performance Liquid Chromatography (HPLC)
[0145] Instrument model: Waters Acquity Arc high performance liquid chromatograph (Waters, US)
[0146] Column: Waters CORTECS C18, 4.6 mm × 150 mm, 2.7 μm
[0147] Test conditions: wavelength 250nm; column temperature 30℃
[0148] Mobile phase: A: 0.1% acetic acid in water; B: 0.05% TFA in acetonitrile
[0149] Injection volume: 5 μL.
[0150] 6. Nuclear Magnetic Resonance Spectroscopy (NMRS)
[0151] Instrument model: Bruker AVANCE III 400 (Bruker, GER)
[0152] Content and test solvent: 1 H-NMR, the test solvent was DMSO-d6.
[0153] 7. Crystal stability test of different pH solutions
[0154] The preparation process of pH buffer is shown in the following table. The crystal samples to be tested were added to 2.0 mL of different buffer media of pH 2-7 to prepare suspensions, and after constant temperature shaking at 25°C for 24 hours, the suspensions were centrifuged; the remaining supernatant was taken to test its pH value, and the remaining solid was subjected to XRPD test.
[0155]
[0156] Instrument: TG16.5 desktop high-speed centrifuge (Shanghai Luxiangyi Centrifuge Instrument Co., Ltd.)
[0157] Conditions: 10000 rpm, centrifugation for 4 minutes.
[0158] 8. Crystal stability test in water and biological media
[0159] The preparation process of the biological medium is shown in the following table. Samples of different crystalline forms were added to 4.0 mL of water and biological medium (FaSSIF, FeSSIF, FaSSGF, FaSSIF / FeSSIF / FaSSGF powder manufacturer Biorelevant, powder item number FFF01, batch number FFF-1219-A) to prepare suspensions, which were shaken at a constant temperature of 37°C for 24 hours, and the pH value of the supernatant at 24 hours was tested, and the remaining solid was subjected to XRPD testing.
[0160]
[0161] Note: FaSSIF: simulates the intestinal fluid in the small intestine of humans in a hungry state before a meal; FeSSIF: simulates the intestinal fluid in the small intestine of humans in a full state after a meal; FaSSGF: simulates the gastric fluid in an empty stomach when humans are hungry.
[0162] The intermediate compounds and / or compounds of the present application can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions known to those skilled in the art, and preferred embodiments include but are not limited to the examples of the present application. When a trade name appears in this article, it is intended to refer to the corresponding commodity or its active ingredient.
[0163] The chemical reactions of the specific embodiments of the present application are carried out in a suitable solvent, which must be suitable for the chemical changes of the present application and the reagents and materials required. In order to obtain the compounds of the present application, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction processes based on the existing embodiments.
[0164] All solvents used in this application were commercially available and used without further purification.
[0165] In order to better understand the content of this application, the following is further described in conjunction with specific examples, but the specific implementation methods are not intended to limit the content of this application. The test methods for which specific conditions are not specified in the following preparation examples, embodiments, comparative examples, test examples or test examples are selected according to conventional methods and conditions, or according to the product instructions.
[0166] Preparation Example 1: Preparation of the compound of formula (A)
[0167]
[0168] Synthesis of intermediate 1a:
[0169] 5-Fluoro-4-iodopyridin-2-amine (1.00 g, 4.20 mmol) was dissolved in ethylene glycol dimethyl ether (20 mL) and water (4 mL), followed by the addition of 4-fluoro-2-methoxyphenylboronic acid (0.71 g, 4.20 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (0.31 g, 0.42 mmol) and potassium carbonate (1.70 g, 12.60 mmol), and the atmosphere was replaced with nitrogen three times to place the entire system under a nitrogen atmosphere. The system was stirred under reflux at 100 ° C and reacted for 4 hours. TLC monitoring showed that there was no residue of the raw material. The mixture was concentrated under reduced pressure and separated and purified by column chromatography (dichloromethane: methanol = 50: 1-10: 1, v / v) to obtain 1a (0.80 g, yield 81%).
[0170] Synthesis of intermediate 1b:
[0171] 1a (0.80 g, 3.40 mmol) was dissolved in N, N-dimethylformamide (30 mL), followed by the addition of (1S, 3R)-3-[(tert-butyloxycarbonyl)amino]cyclohexanecarboxylic acid (0.83 g, 3.40 mmol), 2-(7-azobenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (1.56 g, 4.10 mmol) and N, N-diisopropylethylamine (0.88 g, 6.80 mmol). The whole system was stirred at room temperature overnight, and TLC monitoring showed that no raw material remained. Water (100 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium chloride (50 mL×2), and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and purified by column chromatography (dichloromethane:methanol=50:1-20:1, v / v) to give 1b (0.90 g, yield 58%).
[0172] Synthesis of intermediate 1c:
[0173] 1b (0.90 g, 1.95 mmol) was dissolved in dichloromethane (30 mL), and then trifluoroacetic acid (2 mL) was added under an ice-water bath. The whole system was stirred at room temperature overnight, and TLC was detected until no raw material remained. Water (100 mL) was added to the reaction solution, and then the pH was adjusted to 9-10 with a saturated sodium bicarbonate aqueous solution, extracted with dichloromethane (50 mL × 3), the organic phases were combined, washed with saturated sodium chloride (50 mL × 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. After separation and purification by column chromatography (dichloromethane: methanol = 50: 1-8: 1, v / v), 1c (0.61 g, yield 87%) was obtained.
[0174] Synthesis of final product A:
[0175] 1c (50 mg, 0.138 mmol) was dissolved in N, N-dimethylformamide (5 mL), followed by the addition of glycolic acid (16 mg, 0.21 mmol), 2-(7-azobenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (80 mg, 0.21 mmol) and N, N-diisopropylethylamine (69 μL, 0.42 mmol). The whole system was stirred at room temperature and reacted for 10 hours, and TLC was monitored until no raw material remained. Water (50 mL) was added to the reaction solution, and ethyl acetate was extracted (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride (50 mL × 2), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The final product A (30 mg, yield 52%) was obtained. MS m / z (ESI): 420.2 [M+H] + .
[0176] 1 H NMR (600 MHz, DMSO-d6) δ 10.56 (s, 1H), 8.31 (s, 1H), 8.06 (d, J = 5.4 Hz, 1H), 7.56 (d, J = 9.0 Hz, 1H), 7.34-7.31 (m, 1H), 7.09-7.07 (m, 1H), 6.91-6.88 (m, 1H), 5.38-5.36 (m, 1H), 3.77-3.75 (m, 5H), 3.66-3.63 (m, 1H), 2.61-2.57 (m, 1H), 1.83-1.68 (m, 4H), 1.34-1.26 (m, 4H). Example 1: Preparation of Form I of Compound (A)
[0177] At room temperature, about 200 mg of the sample of Preparation Example 1 was weighed and added to a glass bottle of appropriate volume, ethyl acetate (5 mL) was added, and the mixture was stirred at room temperature for 3 days. The solid was separated by centrifugation and vacuum dried at 50°C. The sample was subjected to X-ray powder diffraction, which showed a crystalline solid (form I, anhydrous form) with good crystallinity. The spectrum is shown in Figure 1 The XRPD diffraction peak data are shown in Table 1. The sample was taken for DSC-TGA test. The DSC graph showed an endothermic peak at 204.33°C. The TGA graph showed that the sample had a weight loss of 0.565% between room temperature and 180°C. Figure 2 .
[0178] Table 1: XRPD diffraction peak data table of Example 1 Form I
[0179]
[0180]
[0181] Note: Peaks with relative peak intensity > 8.0% are selected and listed in the table.
[0182] Example 2: Preparation of Form V of Compound of Formula (A)
[0183] At room temperature, weigh about 200 mg of the sample of Preparation Example 1 in a suitable container and dissolve it in dioxane (4 mL), stir until it is clear, add the clear solution into water (40 mL), continue stirring for 1 hour, centrifuge to obtain a solid, and dry it in vacuo at 50°C. Take the sample for X-ray powder diffraction, which shows a crystalline solid (form V, anhydrous crystal form) with good crystallinity. The spectrum is shown in Figure 3 The XRPD diffraction peak data are shown in Table 2. The sample was taken for DSC-TGA test. The DSC graph showed an endothermic peak at 185.87°C. The TGA graph showed that the sample had a weight loss of 0.926% between room temperature and 170°C. Figure 4 .
[0184] Table 2: XRPD diffraction peak data table of Example 2 Form V
[0185] Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % 6.512 7.9 17.015 11.3 21.024 34.3 9.371 14.6 18.270 30.3 22.823 100.0 11.337 83.5 18.615 7.2 23.541 44.1 13.115 5.2 18.920 5.1 24.436 5.6 16.235 32.2 19.740 9.4 29.455 7.4 16.711 17.8 20.657 8.0
[0186] Note: Peaks with relative peak intensity > 5.0% are selected and listed in the table.
[0187] Example 3: Preparation of Crystalline Form XIII of Compound (A)
[0188] At room temperature, weigh about 80 mg of the sample of Preparation Example 1 in a suitable container and dissolve it in dimethylformamide (0.2 mL). Stir until the solution becomes clear. Add the clear solution into toluene (3 mL) and continue stirring until a solid precipitates. Separate the solid by centrifugation and dry it in vacuo at room temperature.
[0189] Weigh a small amount of the obtained solid sample and spread it on a glass slide, heat it to 180°C on a hot plate and keep it at a constant temperature for 5 minutes, and cool it naturally to room temperature to obtain a solid. Take the sample for X-ray powder diffraction, which shows a crystalline solid (form XIII, anhydrous crystal form) with good crystallinity. The spectrum is shown in Figure 5 The XRPD diffraction peak data are shown in Table 3. The sample was taken for DSC-TGA test. The DSC graph showed that the sample had two endothermic peaks at 194.07℃ and 200.51℃, respectively. The TGA graph showed that the sample had a weight loss of 0.216% between room temperature and 180℃. Figure 6 .
[0190] Table 3: XRPD diffraction peak data table of Example 3 Form XIII
[0191]
[0192]
[0193] Note: Peaks with relative peak intensity > 5.0% are selected and listed in the table.
[0194] Comparative Example 1-2
[0195] A certain amount of the compound sample represented by formula (A) was weighed, 0.4 mL of a binary mixed solvent was added, and after stirring at room temperature for 7 days or at 50° C. for 1 day, no solid was obtained.
[0196] Table 4: Experimental conditions and results of comparative examples 1-2
[0197]
[0198] Test Example 1: Study on the hygroscopicity of different crystalline forms of the compound of formula (A)
[0199] The crystal form I (Example 1) and the crystal form V (Example 2) of the compound of formula (A) were placed in the DVS sample chamber for testing. The samples after DVS were subjected to X-ray powder diffraction.
[0200] Experimental results:
[0201] Table 5: DVS test results of different crystal forms
[0202] Examples and initial crystal form △W(RH=95%) △W(RH=0%) Crystalline form after DVS Example 1 / Crystal Form I +0.13% 0% Crystal form unchanged Example 2 / Crystal Form V +0.06% -0.08% Crystal form unchanged
[0203] The data show that Form I and Form V are not hygroscopic.
[0204] Test Example 2: Solid Stability Test of Different Crystal Forms of Compound (A)
[0205] An appropriate amount of samples of Form I (Example 1) and Form V (Example 2) of the compound of formula (A) were placed in a weighing bottle and left open under high temperature (60°C), high humidity (25°C / 92.5% RH), light (25°C / 4500lux) and accelerated (40°C / 75%RH) conditions for 7 days and 15 days, respectively. The samples were taken for X-ray powder diffraction to investigate the stability of Form I (Example 1) and Form V (Example 2) of the compound of formula (A) under different conditions.
[0206] Table 6: Solid stability test results of different crystal forms
[0207]
[0208] The data show that the crystal form I of Example 1 and the crystal form V of Example 2 can maintain crystal stability and chemical stability under high temperature, high humidity, light and accelerated conditions.
[0209] Test Example 3: Stability test of different crystal forms of the compound of formula (A) in different pH solutions
[0210] The stability of the crystalline form I (Example 1) and the crystalline form V (Example 2) of the compound of formula (A) in a buffer medium of pH 2-7 was investigated.
[0211] Table 7: Stability test results of different crystal forms in different pH solutions
[0212]
[0213] The data show that the crystal form I of Example 1 and the crystal form V of Example 2 can maintain crystal stability in solutions of different pH values. Test Example 4: Stability test of different crystal forms of the compound of formula (A) in biological solvents
[0214] The crystalline stability of Form I (Example 1) and Form V (Example 2) of the compound of formula (A) in pure water and three biological solvents (FaSSIF, FeSSIF and FaSSGF) was investigated.
[0215] Table 8: Stability test results of different crystal forms in biological solvents
[0216]
[0217] The data show that the crystalline form I of Example 1 and the crystalline form V of Example 2 can maintain crystalline stability in water and different biological solvents.
[0218] Test Example 1: Test on the inhibitory effect of the compounds of the present application on CDK9, CDK1, CDK2, CDK4, CDK5, CDK6 and CDK7
[0219] 1. Purpose of the experiment
[0220] Detect the inhibitory effect of compounds on CDK1 / 2 / 4 / 5 / 6 / 7 / 9 kinases and propose effective IC 50 value.
[0221] 2.CDKs detection family
[0222] CDK1 / CDK2 / CDK4 / CDK5 / CDK6 / CDK7 / CDK9
[0223] Table 9: Information on kinases, substrates and ATP in in vitro assays
[0224]
[0225]
[0226] 3. Testing process
[0227] 3.1 Compound dilution
[0228] The compound of formula (A) was diluted with DMSO to 11 concentrations, 3-fold dilution, wherein the highest concentration of the reference compound staurosporine was 1 μM and the highest concentration of the test compound was 10 μM.
[0229] 3.2 Enzyme reaction
[0230] The compound (50 nL) dissolved in DMSO was transferred to the enzyme reaction plate using the sonication technique (Echo). 5 μL of the LCDK enzyme dilution was added to the enzyme reaction plate, centrifuged and incubated at room temperature for 10 minutes. 5 μL of the substrate premix was added to the plate. The final concentrations of substrate and ATP in each well are shown in Table 1. After centrifugation, the reaction was allowed to proceed at 30°C for 120 minutes.
[0231] 3.3 Termination reaction and signal detection
[0232] 10 μL of stop solution was added to each well, and the cells were incubated at room temperature for 120 minutes after centrifugation, and then incubated at 4°C overnight. The signal values were read using the HTRF program on the Envision instrument, and data analysis was performed. 50 (Inhibitory concentration at 50% of the maximum effect) Values are expressed in nM. The results are shown in Table 10.
[0233] Table 10: Inhibitory effects of the compounds represented by formula (A) on CDK1, 2, 4, 5, 6, 7 and 9
[0234] Compound CDK1 CDK2 CDK4 CDK5 CDK6 CDK7 CDK9 Compound A 93.21 563.61 784.82 283.52 2795.36 4443.59 6.92
[0235] The above tests indicate that the compound represented by formula (A) has a selective and effective inhibitory effect on CDK9.
[0236] Experimental Example 2: In vitro inhibitory effect of the compound represented by formula (A) on the proliferation of different tumor cell lines
[0237] 1. Purpose of the experiment
[0238] The in vitro inhibitory effect of the compound represented by formula (A) on the proliferation of various tumor cell lines was investigated.
[0239] 2. Test Principle
[0240] MTT, also known as Thiazolyl Blue, is a tetrazolium salt of a dye that can accept hydrogen atoms. The amber dehydrogenase in the mitochondria of living cells can reduce exogenous MTT to insoluble blue-purple crystals and deposit them in the cells, while dead cells do not have this function. Dimethyl sulfoxide can dissolve the blue-purple complex in the cells, and its light absorption value is measured at a wavelength of 490-550nm using an enzyme-linked immunosorbent assay, which can indirectly reflect the number of cells. Within a certain range of cell numbers, the amount of MTT crystals formed is proportional to the number of cells. The drug to be tested is diluted into different concentrations in turn and added to a 96-well plate. After the drug has acted for a certain period of time, its OD value is measured. The size of the OD value can reflect the number of living cells, and its IC is calculated using SPSS19.0. 50 value.
[0241] 3. Test equipment
[0242] Model 371 CO2 incubator: Thermo
[0243] IX70-142 inverted fluorescence microscope: Olympus
[0244] HFsafe-1500 Biological Safety Cabinet: Shanghai Lishen Scientific Instrument Co., Ltd.
[0245] Varloskan flash microplate reader: Thermo
[0246] Precision electronic balance: Mettler AL204
[0247] TD6 centrifuge: Changsha Xiangrui Centrifuge Co., Ltd.
[0248] 4. Test materials:
[0249] 4.1 Cells and culture medium
[0250]
[0251] Note: Culture medium manufacturer: Gibco.
[0252] 4.2 Test materials
[0253] name Specification Manufacturer Fetal bovine serum 500mL / bottle Cellmo PBS 2L / bag Solarbio DMSO 500mL / bottle recovery MTT 5g / bottle Amresco 0.25% Trypsin-EDTA 500mL / bottle Gibco MEM NEAA 100mL / bottle Gibco Sodium pyruvate 100mL / bottle Gibco Puromycin 1mL Gibco
[0254] 4.3 Reagent preparation
[0255] 5 mg / mL MTT working solution: Weigh 0.5 g of MTT and dissolve it in 100 mL of PBS, filter it through a 0.22 μm microporous filter to sterilize it, and place it in a 4°C refrigerator (for use within two weeks) or -20°C for long-term storage.
[0256] 5. Test methods
[0257] 5.1 Paving
[0258] Suspended cells: Count after centrifugation and resuspending. Prepare a cell suspension of a certain density with complete culture medium, blow and evenly inoculate in a 96-well plate, 100 μL per well, then culture in a CO2 incubator and use for detection after 24 hours of adherence.
[0259] 5.2 Drug preparation
[0260] Weigh an appropriate amount of the compound represented by formula (A), add a calculated amount of DMSO to dissolve, divide into portions, and store at -20°C; prepare a concentration of 10 mM.
[0261] 5.3 Dosing
[0262] The 10 mM concentration stock solution of the compound represented by formula (A) was diluted into DMSO solutions of different concentrations (8 concentrations) of the compound (3-fold dilution, 20× final concentration), and the DMSO solution (10 μL) of the compound of each concentration was taken and diluted with cell culture medium (90 μL) to prepare a working solution (2× final concentration). The working solution (100 μL) of the compound of each concentration was added to a 96-well plate seeded with cells (1× final concentration, the highest final concentration was 1000 nM), 3 replicate wells were set for each drug concentration, and corresponding blank wells (only culture medium) and normal wells (drug concentration was 0) were set, and the culture was continued in a CO2 incubator.
[0263] 6. Detection
[0264] The 96-well plate was taken out and the cell confluence was observed under a microscope. The MTT method was used for detection.
[0265] MTT method: add 20μL of MTT to each well, incubate in the incubator for about 4 hours, discard the liquid in the wells, add 150μL of DMSO to each well, place in an oscillator and shake for 5-10 minutes, and detect with an enzyme-labeled instrument at a wavelength of 550nm.
[0266] The inhibition rate of cell growth was calculated using the following formula: Inhibition rate (%) = (OD value of normal well - OD value of drug-treated well) / (OD value of normal well - OD value of blank well) × 100%
[0267] 7. Data Analysis
[0268] SPSS19.0 statistical software was used to calculate the IC of drugs. 50 value.
[0269] The results of cell proliferation inhibition by the compound represented by formula (A) are shown in Table 11.
[0270] Table 11: Cell proliferation inhibition test data of the compound represented by formula (A)
[0271] Cell Type <![CDATA[IC 50 (nM)]]> MV 4-11 34 Hep3B-Luc 71 SMMC7721-Luc 119 PLC / PRF / 5 292 DU145 85.5 MDA-MB-231 64.4 RPMI-8826 96.8 MM.1S 22.3 SU-DHL-4 11.2 Jeko-1 21.6
[0272] Experimental conclusion: According to the data in the table, the compound represented by formula (A) has a strong inhibitory effect on various tumor cell lines.
[0273] Experimental Example 3: In vitro hERG inhibitory activity investigation
[0274] 1. Purpose of the test:
[0275] The rapidly activated human delayed rectifier outward potassium current (IKr) is mainly mediated by the hERG ion channel and is involved in the repolarization of human cardiomyocytes. Drug blockade of this current is the main cause of clinical QT interval prolongation syndrome, even acute arrhythmia and even sudden death. The whole-cell patch clamp technique was used to detect the blocking effect of the compound shown in formula (A) on the hERG channel in the CHO-K1 cell line stably expressing the hERG channel, and the half inhibitory concentration IC of the compound was determined. 50 , as part of a comprehensive cardiac safety assessment, to conduct a preliminary evaluation of its safety in vitro screening for cardiotoxicity.
[0276] 2. Test methods:
[0277] This test includes the following aspects:
[0278] hERG currents were recorded using the manual patch clamp technique in CHO-K1 cells stably expressing hERG channels;
[0279] The inhibition rate of each concentration was calculated based on the hERG tail current;
[0280] Each compound was tested at 5 concentrations and the IC 50 value;
[0281] Three cells were tested at each concentration;
[0282] A positive control drug.
[0283] The hERG current was recorded using the whole-cell patch clamp technique. The cell suspension was added to the cell trough and placed on an upright microscope stage. After the cells adhered to the wall, they were perfused with extracellular fluid at a flow rate of 1-2 mL / min. The glass microelectrode was pulled in two steps by a microelectrode puller, and its water resistance was 2-5 MΩ. After establishing the whole-cell recording, the clamping potential was maintained at -80 mV. When a voltage stimulus was given, the hERG tail current was elicited by depolarizing to +60 mV and then repolarizing to -50 mV. All recordings were performed after the current stabilized. Extracellular perfusion administration started with a low concentration, and each concentration was given for 5-10 minutes until the current stabilized before the next concentration was given. The half-maximal inhibitory concentration (IC 50 ) is obtained by best fitting the Logistic equation.
[0284] Amitriptyline is one of the most widely used drugs for blocking hERG current, so it was used as a positive control drug in this study.
[0285] 3. The results are shown in Table 12:
[0286] Table 12: IC values of the compounds of formula (A) on hERG current recorded on CHO-K1 stable cell line 50 Numeric
[0287]
[0288] In the above experiment, the IC of hERG current inhibition by the positive control drug amitriptyline was 50 The results are consistent with the historical results of the test party and the results reported in the literature, indicating that the results of this test are credible. The above test results show that the compound represented by formula (A) cannot achieve half inhibition of hERG current at the highest test concentration, so IC cannot be measured. 50 This indicates that within the detection concentration range of this experiment, the compound represented by formula (A) has no obvious inhibitory effect on the hERG channel, which to a certain extent reflects that the compound represented by formula (A) has low or no cardiotoxicity, which has positive significance for drug safety evaluation.
[0289] Experimental Example 4: Investigation of the in vivo anti-tumor activity of the drug - In vivo pharmacodynamics of the compound represented by formula (A) in a subcutaneous xenograft tumor model of human acute myeloid leukemia MV4-11 cells
[0290] Cell culture: IMDM medium containing 10% fetal bovine serum (FBS), 37°C, 5% CO2.
[0291] NODSCID mice, female, 6-8 weeks old, weighing approximately 18-22 g, were inoculated subcutaneously on the right back with 0.1 mL (1×10 8 )MV 4-11 cells. When the average tumor volume reached 150 cubic millimeters, administration began. The dosage and method of administration are shown in the table below. The tumor volume was measured twice a week, and the volume was measured in cubic millimeters. When the average tumor volume of the solvent group grew to more than 800 cubic millimeters, administration was terminated, and the difference in average tumor volume between the test compound group and the solvent group was compared. The anti-tumor efficacy of the compound was evaluated by TGI (%). TGI (%) reflects the tumor growth inhibition rate.
[0292] Solvent: DMSO: HP-β-CD (0.5 g / mL): water in a ratio of 2%: 20%: 78% (v / v / v).
[0293] Calculation of TGI (%): TGI (%) = [1-(average tumor volume of a treatment group at the end of administration-average tumor volume of the treatment group at the beginning) / (average tumor volume of the solvent control group at the end of administration-average tumor volume of the solvent control group at the beginning)] × 100%.
[0294] The results are shown in Table 13.
[0295] Table 13: In vivo tumor inhibition test data
[0296] Group Number of animals Dosage Dosage Dosing days TGI (%) Solvent Group 5 qd,po -- 16 -- Compound A 5 qd,po 5mg / kg 16 62.9
[0297] Test conclusion:
[0298] The compound represented by formula (A) exhibits good in vivo efficacy in a subcutaneous xenograft tumor model of human acute myeloid leukemia MV 4-11 cells and has a significant tumor inhibition effect.
[0299] Experimental Example 5: Investigation of the in vivo anti-tumor activity of the drug - In vivo efficacy of the compound represented by formula (A) in a subcutaneous xenograft tumor model of human promyelocytic acute leukemia HL-60 cells.
[0300] Cell culture: IMDM medium containing 20% fetal bovine serum (FBS), 37°C, 5% CO2;
[0301] NU / NU mice, female, 6-8 weeks old, weighing approximately 18-22 g, were subcutaneously inoculated with 0.1 mL of HL-60 cell suspension (containing approximately 1×10 cells) in the axilla of the right forelimb of each mouse. 7 When the average tumor volume reaches 150 cubic millimeters, the drug administration begins. The dosage and administration method are shown in the table below. The tumor volume is measured 2-3 times a week, and the volume is measured in cubic millimeters. When the average tumor volume of the solvent group grows to more than 800 cubic millimeters, the drug administration is terminated, and the difference in average tumor volume between the test compound group and the solvent group is compared. The anti-tumor efficacy of the compound is evaluated by TGI (%). TGI (%) reflects the tumor growth inhibition rate.
[0302] Solvent: DMSO: HP-β-CD (0.5 g / mL): water in a ratio of 2%: 20%: 78% (v / v / v).
[0303] Calculation of TGI (%): TGI (%) = [1-(average tumor volume of a treatment group at the end of administration-average tumor volume of the treatment group at the beginning) / (average tumor volume of the solvent control group at the end of administration-average tumor volume of the solvent control group at the beginning)] × 100%.
[0304] The results are shown in Table 14.
[0305] Table 14: In vivo tumor inhibition test data
[0306] Group Number of animals Dosage Dosage Dosing days TGI (%) Solvent Group 5 qd,po -- 9 -- Compound A 5 qd,po 5mg / kg 9 58.0
[0307] Test conclusion:
[0308] The compound represented by formula (A) exhibits good in vivo efficacy in a subcutaneous xenograft tumor model of human promyelocytic acute leukemia HL-60 cells. Nine days after the start of administration, the compound represented by formula (A) has a significant tumor inhibition effect.
[0309] Test Example 6: Investigation of drug toxicity to mice
[0310] Experimental animals: ICR mice (5 weeks old), half male and half female
[0311] Solvent: Solvent: DMSO: HP-β-CD (0.5 g / mL): water in a ratio of 2%: 20%: 78% (v / v / v).
[0312] Test method: ICR mice were divided into 7 groups according to their weight, with 5 males and 5 females in each group. The drug was administered by gavage once a day for 7 consecutive days. The dosage and results are shown in the table below.
[0313] Test results:
[0314]
[0315] Test conclusion: With increasing doses, the control drug BAY1251152 showed dose-dependent toxicity, and the number of animal deaths increased; Compound A of the present application did not cause death of experimental animals at the same dose as the control drug, which shows that the tolerability of Compound A of the present application in female and male animals is significantly better than that of the control drug BAY1251152.
[0316] Although the foregoing application has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent to one of ordinary skill in the art from the teachings of this application that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Claims
1. Crystalline Form I of the compound represented by formula (A), in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 13.3±0.2°, 19.4±0.2°, 20.1±0.2°, 23.0±0.2°, 26.1±0.2°.
2. The crystalline form I according to claim 1, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 13.3±0.2°, 19.4±0.2°, 20.1±0.2°, 20.7±0.2°, 21.5±0.2°, 23.0±0.2°, 26.1±0.2°.
3. The crystalline form I according to claim 1, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 13.3±0.2°, 19.4±0.2°, 20.1±0.2°, 20.7±0.2°, 21.5±0.2°, 23.0±0.2°, 26.1±0.2°, 26.6±0.2°.
4. The crystalline form I according to claim 1, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.3±0.2°, 13.3±0.2°, 19.4±0.2°, 20.1±0.2°, 20.7±0.2°, 21.5±0.2°, 23.0±0.2°, 26.1±0.2°, 26.6±0.2°.
5. The crystalline form I according to claim 1, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.3±0.2°, 12.4±0.2°, 13.3±0.2°, 18.6±0.2°, 19.4±0.2°, 20.1±0.2°, 20.7±0.2°, 21.5±0.2°, 23.0±0.2°, 26.1±0.2°, 26.6±0.2°.
6. The crystalline form I according to claim 1, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.3±0.2°, 12.4±0.2°, 13.3±0.2°, 18.6±0.2°, 19.4±0.2°, 20.1±0.2°, 20.4±0.2°, 20.7±0.2°, 21.5±0.2°, 22.0±0.2°, 23.0±0.2°, 26.1±0.2°, 26.6±0.2°.
7. The crystalline form I according to claim 1, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.3±0.2°, 12.4±0.2°, 13.1±0.2°, 13.3±0.2°, 15.4±0.2°, 18.6±0.2°, 19.4±0.2°, 19.5±0.2°, 20.1±0.2°, 20.4±0.2°, 20.7±0.2°, 21.5±0.2°, 22.0±0.2°, 23.0±0.2°, 26.1±0.2°, 26.6±0.2°.
8. The crystalline form I according to claim 1, in, Using Cu-Kα radiation, it has an X-ray powder diffraction pattern substantially as shown in FIG. 1 .
9. The crystalline form I according to claim 1, wherein the differential scanning calorimetry curve thereof has an endothermic peak at 204.33±5°C.
10. The crystalline form I according to claim 1, which has a DSC spectrum substantially as shown in Figure 2.
11. Crystalline form V of the compound represented by formula (A), in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 11.3±0.2°, 16.2±0.2°, 18.3±0.2°, 21.0±0.2°, 22.8±0.2°.
12. The crystalline form V according to claim 11, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 11.3±0.2°, 16.2±0.2°, 18.3±0.2°, 21.0±0.2°, 22.8±0.2°, 23.5±0.2°.
13. The crystalline form V according to claim 11, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.4±0.2°, 11.3±0.2°, 16.2±0.2°, 18.3±0.2°, 19.7±0.2°, 21.0±0.2°, 22.8±0.2°, 23.5±0.2°.
14. The crystalline form V according to claim 11, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 6.5±0.2°, 9.4±0.2°, 11.3±0.2°, 16.2±0.2°, 16.7±0.2°, 18.3±0.2°, 19.7±0.2°, 21.0±0.2°, 22.8±0.2°, 23.5±0.2°.
15. The crystalline form V according to claim 11, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 6.5±0.2°, 9.4±0.2°, 11.3±0.2°, 16.2±0.2°, 16.7±0.2°, 17.0±0.2°, 18.3±0.2°, 19.7±0.2°, 20.7±0.2°, 21.0±0.2°, 22.8±0.2°, 23.5±0.2°.
16. The crystalline form V according to claim 11, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 6.5±0.2°, 9.4±0.2°, 11.3±0.2°, 13.1±0.2°, 16.2±0.2°, 16.7±0.2°, 17.0±0.2°, 18.3±0.2°, 19.7±0.2°, 20.7±0.2°, 21.0±0.2°, 22.8±0.2°, 23.5±0.2°, 24.4±0.2°.
17. The crystalline form V according to claim 11, in, Using Cu-Kα radiation, it has an X-ray powder diffraction pattern substantially as shown in FIG. 3 .
18. The crystalline form V according to claim 11, in, Its differential scanning calorimetry curve has an endothermic peak at 185.87±5℃.
19. The crystalline form V according to claim 11, in, It has a DSC spectrum substantially as shown in FIG4 .
20. Crystalline form XIII of the compound represented by formula (A), in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 14.3±0.2°, 15.8±0.2°, 17.8±0.2°, 19.1±0.2°, 20.8±0.2°.
21. The crystalline form XIII according to claim 20, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.5±0.2°, 14.3±0.2°, 15.8±0.2°, 17.8±0.2°, 19.1±0.2°, 20.8±0.2°, 24.4±0.2°.
22. The crystalline form XIII according to claim 20, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.5±0.2°, 14.3±0.2°, 15.8±0.2°, 17.8±0.2°, 18.2±0.2°, 19.1±0.2°, 20.8±0.2°, 24.4±0.2°, 26.3±0.2°.
23. The crystalline form XIII according to claim 20, in, Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.5±0.2°, 14.3±0.2°, 15.8±0.2°, 16.6±0.2°, 17.8±0.2°, 18.2±0.2°, 19.1±0.2°, 20.8±0.2°, 24.4±0.2°, 26.3±0.2°, 26.9±0.2°.
24. The crystalline form XIII according to claim 20, in, Using Cu-Kα radiation, it has an X-ray powder diffraction pattern substantially as shown in FIG5 .
25. A crystalline composition comprising Form I according to any one of claims 1 to 10, Form V according to any one of claims 11 to 19, Form XIII according to any one of claims 20 to 24, or two or more thereof.
26. A pharmaceutical composition comprising the crystalline composition of claim 25.
27. The pharmaceutical composition according to claim 26, in, The pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
28. A pharmaceutical composition comprising the crystalline form I according to any one of claims 1-10, the crystalline form V according to any one of claims 11-19, and the crystalline form XIII according to any one of claims 20-24.
29. The pharmaceutical composition according to claim 28, in, The pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
30. Use of the crystalline form I of any one of claims 1-10, the crystalline form V of any one of claims 11-19, the crystalline form XIII of any one of claims 20-24, the crystalline composition of claim 25, or the pharmaceutical composition of any one of claims 26-29 in the preparation of a medicament as a CDK9 inhibitor.
31. Use of the crystalline form I of any one of claims 1-10, the crystalline form V of any one of claims 11-19, the crystalline form XIII of any one of claims 20-24, the crystalline composition of claim 25, or the pharmaceutical composition of any one of claims 26-29 in the preparation of a medicament for treating a CDK9-mediated disease.
32. The use according to claim 31, in, The CDK9-mediated disease is a cell proliferative disease or an inflammatory disease.
33. The use according to claim 31, in, The CDK9-mediated disease refers to a disease involving changes in the CDK9 gene, protein, activity or expression thereof.
34. The use according to claim 32, in, The cell proliferative disease is a tumor.
35. The use according to claim 34, in, The tumor is a blood tumor or a solid tumor.
36. The use according to claim 34, in, The tumor is a relapsed or refractory blood tumor or solid tumor.
37. The use according to claim 34, in, The tumor is a malignant blood tumor or an advanced solid tumor.
38. The use according to claim 34, in, The tumor is an advanced malignant blood tumor or an advanced malignant solid tumor.
39. The use according to claim 34, in, The tumor is a relapsed or refractory advanced malignant hematological tumor or an advanced malignant solid tumor.
40. The use according to claim 35, in, The blood tumor is leukemia, lymphoma or myeloma.
41. The use according to claim 40, in, The leukemia is acute myeloid leukemia; the lymphoma is non-Hodgkin's lymphoma; and the myeloma is multiple myeloma.
42. The use according to claim 40 or 41, in, The lymphoma is mantle cell lymphoma or diffuse large B-cell lymphoma.
43. The use according to claim 35, in, The solid tumor is selected from liver cancer, breast cancer and prostate cancer.
44. The use according to claim 43, in, The breast cancer is triple-negative breast cancer.
Citation Information
Patent Citations
Inhibitors of protein kinases
WO2009047359A1
5-fluoro- n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
WO2014076091A1
Bipyridines useful for the treatment of proliferative diseases
CN102471310A
Pyrazinylpyridines useful for the treatment of proliferative diseases
CN102482265A
Inhibitors of protein kinases
CN102834380A
